E2F1 inhibition mediates cell death of metastatic melanoma

Melanoma is one of the most lethal cancers when it reaches a metastatic stage. Despite advancements in targeted therapies (BRAF inhibitors) or immunotherapies (anti-CTLA-4 or anti-PD1), most patients with melanoma will need additional treatment. Thus, there is an urgent need to develop new therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Rouaud, Florian, Hamouda-Tekaya, Nedra, Cerezo, Michaël, Abbe, Patricia, Zangari, Joséphine, Hofman, Veronique, Ohanna, Mickaël, Mograbi, Baharia, El-Hachem, Najla, Benfodda, Zohra, Lebeau, Alexandre, Tulic, Meri K., Hofman, Paul, Bertolotto, Corine, Passeron, Thierry, Annicotte, Jean-Sébastien, Ballotti, Robert, Rocchi, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943238/
https://www.ncbi.nlm.nih.gov/pubmed/29743521
http://dx.doi.org/10.1038/s41419-018-0566-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943238/
https://www.ncbi.nlm.nih.gov/pubmed/29743521
http://dx.doi.org/10.1038/s41419-018-0566-1

Ejemplares similares